Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 14,455.0 | 12,574.0 | 14,109.0 | 14,768.0 | 14,314.0 | 13,599.0 | 13,405.0 | 14,484.0 |
| Revenue growth | 15.0% | -10.9% | -4.5% | 3.2% | 5.3% | 1.4% | -7.4% | 2.5% |
| Cost of goods sold | 8,489.0 | 7,375.0 | 8,187.0 | 8,604.0 | 8,306.0 | 7,908.0 | 7,888.0 | 8,673.0 |
| Gross profit | 5,966.0 | 5,199.0 | 5,922.0 | 6,164.0 | 6,008.0 | 5,691.0 | 5,517.0 | 5,811.0 |
| Gross margin | 41.3% | 41.3% | 42.0% | 41.7% | 42.0% | 41.8% | 41.2% | 40.1% |
| Selling, general and administrative | 0.0 | 0.0 | 0.0 | 0.0 | -95.0 | 0.0 | 0.0 | 2,923.0 |
| EBITA | 3,610.0 | 3,036.0 | 3,561.0 | 3,773.0 | 3,596.0 | 3,280.0 | 3,100.0 | 3,133.0 |
| EBITA margin | 25.0% | 24.1% | 25.2% | 25.5% | 25.1% | 24.1% | 23.1% | 21.6% |
| Amortization of intangibles | 133.0 | 154.0 | 159.0 | 189.0 | 206.0 | 224.0 | 233.0 | 245.0 |
| EBIT | 3,477.0 | 2,882.0 | 3,402.0 | 3,584.0 | 3,390.0 | 3,056.0 | 2,867.0 | 2,888.0 |
| EBIT margin | 24.1% | 22.9% | 24.1% | 24.3% | 23.7% | 22.5% | 21.4% | 19.9% |
| Pre-tax income | 3,326.0 | 2,704.0 | 3,288.0 | 3,394.0 | 3,270.0 | 2,908.0 | 2,719.0 | 2,699.0 |
| Income taxes | 632.0 | 595.0 | 767.0 | 831.0 | 1,583.0 | 873.0 | 820.0 | 809.0 |
| Tax rate | 19.0% | 22.0% | 23.3% | 24.5% | 48.4% | 30.0% | 30.2% | 30.0% |
| Earnings from continuing ops | 2,694.0 | 2,109.0 | 2,521.0 | 2,563.0 | 1,687.0 | 2,035.0 | 1,899.0 | 1,890.0 |
| Earnings from discontinued ops | | | | | | | | 1,056.0 |
| Net income | 2,694.0 | 2,109.0 | 2,521.0 | 2,563.0 | 1,687.0 | 2,035.0 | 1,899.0 | 2,946.0 |
| Net margin | 18.6% | 16.8% | 17.9% | 17.4% | 11.8% | 15.0% | 14.2% | 20.3% |
| |
| Diluted EPS | $8.51 | $6.63 | $7.74 | $7.60 | $4.86 | $5.70 | $5.13 | $4.67 |
| Shares outstanding (diluted) | 316.4 | 318.3 | 325.6 | 337.1 | 346.8 | 357.1 | 370.1 | 404.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|